DadFinStart your free week
DadFin › Stocks › Healthcare › TWST

Twist Bioscience Corporation (TWST) stock score

Healthcare · Biotechnology · United States

$159.78 ▲ +5.08% today

77.3
Dad Score, out of 100
good

Twist Bioscience Corporation (TWST) is a Biotechnology company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 77.3 out of 100 on the Dad Score, a good reading that places the business ahead of 77% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #201 of 974. Its strongest axes are growth, price action and conviction; its weakest is macro.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Average
Quality
Average
Growth
Above average
Price action
Above average
Risk
Average
Conviction
Above average
Liquidity
Strong
Macro
Below average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)0.0×
P/E (forward)-298.3×
Dividend yield0.00%
Return on capital-14.0%
Operating margin-30.6%
Revenue growth (YoY)+20.3%
FCF yield-0.6%
Net debt / EBITDA3.00×
Piotroski F-Score4 / 9
52-week change+492.4%
Market cap$12.5B
Next earningsNov 16, 2026

What subscribers see on TWST

Start your free weekSubscriber? Open the full research →

Biotechnology peers

StockCompanyDad ScoreBandMarket cap
VRTXVertex Pharmaceuticals Incorporate51.2middling$127.8B
MRNAModerna, Inc.23.4weak$75.9B
REGNRegeneron Pharmaceuticals, Inc.91.1strong$75.7B
ARGXargenx SE55.1middling$57.5B
RVMDRevolution Medicines, Inc.40.6middling$44.3B
ONCBeOne Medicines AG94.5strong$40.7B
RPRXRoyalty Pharma plc70.8good$33.0B
ALNYAlnylam Pharmaceuticals, Inc.83.8good$29.4B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.